Biocartesian

Biocartesian, founded in San Francisco in 2023 by Ian Dardani and Jess Li, develops a proprietary platform that converts biological information from tissues or cultured cells into digital molecular maps. Their technology enables high-resolution DNA/RNA/protein profiling within tissue sections as well as high-throughput omics studies in cell cultures. This approach supports the discovery of new biomarkers, therapeutic targets, and precision medicine strategies. The company’s capabilities also include pooled optical CRISPR screens for functional genomics studies. As of now, there are no reported clinical results since the company focuses on enabling disease biology research rather than direct therapeutic development.